EP 1853269 A4 20110907 - AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
Title (en)
AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
Title (de)
AMIDDERIVATE ALS IONENKANALLIGANDEN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN SOWIE VERFAHREN DAMIT
Title (fr)
DERIVES D'AMIDE EN TANT QUE LIGANDS DE CANAL IONIQUE, COMPOSITIONS PHARMACEUTIQUES ET METHODES D'UTILISATION ASSOCIEES
Publication
Application
Priority
- US 2006006615 W 20060224
- US 65698405 P 20050228
- US 71044505 P 20050823
- US 77610606 P 20060223
- US 77593006 P 20060223
- US 77594506 P 20060223
- US 77594906 P 20060223
- US 77603306 P 20060223
- US 77605606 P 20060223
- US 77605706 P 20060223
- US 77605806 P 20060223
- US 77606406 P 20060223
- US 77610506 P 20060223
- US 83990306 P 20060824
- US 83999406 P 20060824
Abstract (en)
[origin: WO2006093832A2] Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
IPC 8 full level
A61K 31/4709 (2006.01); A61K 31/538 (2006.01); C07D 405/14 (2006.01); C07D 413/02 (2006.01)
CPC (source: EP KR)
A61K 31/538 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 1/02 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/08 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 7/10 (2017.12 - EP); A61P 7/12 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 11/08 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 15/08 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/06 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 209/08 (2013.01 - EP); C07D 209/48 (2013.01 - EP); C07D 209/50 (2013.01 - EP); C07D 215/06 (2013.01 - EP); C07D 215/38 (2013.01 - EP); C07D 217/02 (2013.01 - EP); C07D 217/22 (2013.01 - EP); C07D 231/56 (2013.01 - EP); C07D 235/06 (2013.01 - EP); C07D 235/08 (2013.01 - EP); C07D 237/28 (2013.01 - EP); C07D 241/42 (2013.01 - EP); C07D 263/58 (2013.01 - EP); C07D 265/16 (2013.01 - EP); C07D 265/36 (2013.01 - EP); C07D 267/14 (2013.01 - EP); C07D 277/46 (2013.01 - EP); C07D 277/64 (2013.01 - EP); C07D 295/088 (2013.01 - EP); C07D 295/13 (2013.01 - EP); C07D 317/46 (2013.01 - KR); C07D 317/52 (2013.01 - EP); C07D 317/58 (2013.01 - EP); C07D 319/16 (2013.01 - KR); C07D 319/18 (2013.01 - EP); C07D 333/54 (2013.01 - EP); C07D 401/12 (2013.01 - EP); C07D 405/12 (2013.01 - EP); C07D 405/14 (2013.01 - KR); C07D 413/12 (2013.01 - EP); C07D 471/04 (2013.01 - EP); C07D 491/052 (2013.01 - EP); C07D 498/04 (2013.01 - EP)
Citation (search report)
- [XDP] WO 2005046683 A1 20050526 - RENOVIS INC [US], et al
- [IA] WO 2004096784 A1 20041111 - ASTRAZENECA AB [SE], et al
- See references of WO 2006093832A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
WO 2006093832 A2 20060908; WO 2006093832 A3 20070322; AP 2007004119 A0 20070831; AU 2006218824 A1 20060908; AU 2007221118 A1 20070907; CA 2600933 A1 20060908; EP 1853269 A2 20071114; EP 1853269 A4 20110907; EP 1954132 A2 20080813; EP 1954132 A4 20091104; JP 2008531690 A 20080814; KR 20070119655 A 20071220; NO 20074739 L 20071115; WO 2007100758 A2 20070907; WO 2007100758 A3 20071129
DOCDB simple family (application)
US 2006006615 W 20060224; AP 2007004119 A 20060224; AU 2006218824 A 20060224; AU 2007221118 A 20070222; CA 2600933 A 20060224; EP 06736043 A 20060224; EP 07751654 A 20070222; JP 2007558085 A 20060224; KR 20077022045 A 20070927; NO 20074739 A 20070917; US 2007004912 W 20070222